Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Recent Advances In Microparticle And Nanoparticle Delivery Vehicles For Mucosal Vaccination.

E. McNeela, E. Lavelle
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The great potential of mucosal vaccination is widely accepted but progress in the clinical development of subunit mucosal vaccines has been disappointing. Of the available approaches, the use of polymer-based microparticles is attractive because these delivery vehicles can be specifically tailored for vaccines and they offer the potential for integration of adjuvant. Here we address recent developments in the use of particulates as mucosal vaccines and the potential of novel targeting strategies, formulation approaches and adjuvant combinations to enhance the efficacy of particle-based mucosal vaccines. This review discusses the current status of mucosal vaccines based on particles and highlights several of the strategies that are currently under investigation for improving their immunogenicity. These include enhancing the stability of formulations in the luminal environment, increasing uptake by specifically targeting particles to mucosal inductive sites, and augmenting immunogenicity through co-formulation with immunostimulatory agents.
This paper references
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
10.1128/IAI.67.7.3587-3592.1999
Protective Immunity of Microsphere-Based Mucosal Vaccines against Lethal Intranasal Challenge withStreptococcus pneumoniae
S. Y. Seong (1999)
10.1111/j.2042-7158.1998.tb03298.x
Conference Science Medal Lecture: Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration *
D. O'hagan (1998)
10.1016/J.JCONREL.2005.10.010
Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
J. Kazzaz (2006)
10.1152/AJPGI.1994.267.6.G1108
Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines.
P. Giannasca (1994)
10.1093/INFDIS/167.1.84
Oral immunization with influenza virus in biodegradable microspheres.
Z. Moldoveanu (1993)
10.1016/S0939-6411(97)00096-9
Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems☆
E. Haltner (1997)
10.1056/NEJMoa0807381
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
P. Bejon (2008)
10.1111/j.1398-9995.2009.01945.x
Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction
N. Saint-Lu (2009)
10.1016/J.YMETH.2006.05.017
Microparticle-based technologies for vaccines.
D. O'hagan (2006)
10.1080/10611860600849464
Microcapsules formulated in the enteric coating copolymer Eudragit L100 as delivery systems for oral vaccination against infections by gastrointestinal nematode parasites
M. Dea-Ayuela (2006)
10.1016/J.JCONREL.2004.09.003
The role of branched polyesters and their modifications in the development of modern drug delivery vehicles.
L. A. Dailey (2005)
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.
S. Challacombe (1992)
10.1038/mi.2007.6
The immune geography of IgA induction and function
A. Macpherson (2008)
10.1073/PNAS.97.2.811
Cationic microparticles: A potent delivery system for DNA vaccines.
M. Singh (2000)
10.1016/S0168-3659(00)00226-1
Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.
J. Kazzaz (2000)
10.1007/s00018-005-5290-1
Generation of improved mucosal vaccines by induction of innate immunity
E. Lavelle (2005)
10.1016/0962-8924(92)90099-9
Transepithelial transport and mucosal defence I: the role of M cells.
M. Neutra (1992)
10.1016/S0928-0987(01)00175-0
Oral vaccination in man using antigens in particles: current status.
D. Brayden (2001)
10.1016/S0169-409X(98)00012-X
Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines.
Gupta (1998)
10.1016/J.VACCINE.2006.01.011
Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
K. S. Jaganathan (2006)
Microencapsulation using emulsification/solvent evaporation: an overview of techniques and applications.
P. Watts (1990)
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1002/JMV.20100
Induction of HIV‐specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV‐capturing nanospheres in macaques
A. Miyake (2004)
10.1177/194589240501900303
Expression of TLR2 and TLR4 Messenger RNA in the Epithelial Cells of the Nasal Airway
Z. Dong (2005)
10.1016/J.BMC.2003.09.002
Identification of novel small-molecule Ulex europaeus I mimetics for targeted drug delivery.
Christa Hamashin (2003)
Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
K. Maloy (1994)
10.1016/J.JCONREL.2005.09.015
Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice.
A. Luzardo-Alvarez (2005)
10.1016/J.IJPHARM.2003.07.015
Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin.
T. Morçöl (2004)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/0168-3659(94)00084-8
Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (d,l-lactic acid-co-glycolic acid) microspheres
T. Park (1995)
Pharmaceutical approaches to colon targeted drug delivery systems.
M. Chourasia (2003)
10.1128/IAI.67.9.4400-4406.1999
Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants
G. Douce (1999)
10.1016/J.IMLET.2005.03.020
Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles.
F. Roth-Walter (2005)
10.1016/S0264-410X(96)00149-1
Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres.
Y. Tabata (1996)
10.1080/026520400417630
In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters.
S. Lin (2000)
10.1080/10408690390826455
Chitin — The Undisputed Biomolecule of Great Potential
R. Tharanathan (2003)
10.1073/pnas.0608611104
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
S. Lai (2007)
10.1084/JEM.183.4.1865
A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph
K. Matsuno (1996)
10.1016/S0169-409X(00)00127-7
The potential use of receptor-mediated endocytosis for oral drug delivery.
G. Russell-Jones (2001)
10.1016/0378-5173(94)90438-3
The potential use of tomato lectin for oral drug delivery. 1. Lectin binding to rat small intestine in vitro
B. Naisbett (1994)
10.1002/JMV.10279
Mucosal immunization with inactivated HIV‐1‐capturing nanospheres induces a significant HIV‐1‐specific vaginal antibody response in mice
Takami Akagi (2003)
10.4049/jimmunol.170.3.1462
Differential Expression of the Murine Mannose-Binding Lectins A and C in Lymphoid and Nonlymphoid Organs and Tissues 1
S. Wagner (2003)
10.1016/J.INTIMP.2009.01.012
Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses.
Par Bahadur Pun (2009)
10.1016/J.VACCINE.2006.03.001
Use of an oral diphtheria vaccine in human.
N. Rydell (2006)
10.1046/j.1365-2567.1998.00441.x
Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses
Ugozzoli (1998)
10.1128/IAI.64.2.489-494.1996
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
D. I. Jones (1996)
THE INTESTINAL UPTAKE OF PARTICLES AND THE IMPLICATIONS FOR DRUG AND ANTIGEN DELIVERY
O'Hagan Dt (1996)
10.1128/CDLI.9.5.1021-1024.2002
Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection against Herpes Simplex Virus Type 2
Q. He (2002)
10.1038/NM1096-1116
Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection
J. Whittum-Hudson (1996)
10.1007/s004289900177
Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans
Y. Fujimura (2000)
10.1016/J.IMLET.2004.10.026
Toll-like receptor 9 is expressed on follicle-associated epithelia containing M cells in swine Peyer's patches.
T. Shimosato (2005)
10.1016/S0264-410X(00)00433-3
Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
M. Conway (2001)
10.1128/IAI.71.1.504-509.2003
Cholera Toxin Induces Migration of Dendritic Cells from the Subepithelial Dome Region to T- and B-Cell Areas of Peyer's Patches
V. Shreedhar (2003)
10.1023/A:1011063232257
Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice
T. Jung (2004)
10.1016/J.IJPHARM.2006.03.047
Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
M. Tafaghodi (2006)
10.1016/S0264-410X(01)00051-2
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
J. Lambert (2001)
10.1016/S0171-2985(11)80470-5
Controlled-release vaccines--biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles.
M. T. Aguado (1992)
10.1016/S0264-410X(02)00662-X
Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice.
M. Iqbal (2003)
10.1016/S0264-410X(01)00484-4
Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge.
M. Kende (2002)
10.1016/J.ADDR.2004.09.009
Exploiting receptor biology for oral vaccination with biodegradable particulates.
N. Foster (2005)
10.1002/eji.200737909
IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function
I. Monteleone (2008)
10.1016/0142-9612(88)90033-6
Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage.
Y. Tabata (1988)
10.1016/S0264-410X(99)00140-1
PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems.
A. Delgado (1999)
10.1007/BF00229081
Nasal lymphoid tissue in the rat
B. J. Spit (2004)
10.1016/S0264-410X(02)00435-8
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.
I. Gutierro (2002)
10.1016/S0169-409X(98)00008-8
Aluminum compounds as vaccine adjuvants.
Gupta (1998)
10.1586/14760584.6.3.401
Implication of nanoparticles/microparticles in mucosal vaccine delivery
S. Vyas (2007)
10.1016/J.JCONREL.2005.01.014
Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu.
Zoë K Carpenter (2005)
10.1016/j.drudis.2009.02.009
The path to a successful vaccine adjuvant--'the long and winding road'.
D. O’Hagan (2009)
10.1002/JBM.10019
Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo.
K. D. Newman (2002)
10.1046/j.1440-1711.2001.01011.x
Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes
J. Reece (2001)
10.1073/pnas.0804897106
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Fiona A. Sharp (2009)
10.1006/VIRO.1999.9751
Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles.
J. Herrmann (1999)
10.1006/VIRO.1999.0093
Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
H. Kaneko (2000)
10.1016/S0264-410X(97)00222-3
Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo.
N. Foster (1998)
10.1586/14787210.7.1.21
Modern Mucosal Vaccines, Adjuvants and Microbicides
M. Cranage (2009)
10.1016/J.IT.2005.11.005
Triggering TLR signaling in vaccination.
D. van Duin (2006)
10.3109/10611860009009208
Tissue Distribution and Persistence in Mice of Plasmid DNA Encapsulated in a PLGA-Based Microsphere Delivery Vehicle
L. Lunsford (2000)
10.1146/ANNUREV.IMMUNOL.20.083001.084359
Innate immune recognition.
C. Janeway (2002)
10.1080/10611860701637982
M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B
P. Gupta (2007)
10.1016/J.VACCINE.2007.09.044
Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles.
Hesham H. Salman (2007)
10.1016/J.ADDR.2005.12.003
Needle-free vaccine delivery.
E. Giudice (2006)
10.1158/0008-5472.CAN-04-0138
Targeting Dendritic Cells with Antigen-Containing Liposomes
C. L. van Broekhoven (2004)
10.4049/jimmunol.176.7.4275
TLRs Regulate the Gatekeeping Functions of the Intestinal Follicle-Associated Epithelium1
Sophie M Chabot (2006)
10.1007/BF02913722
Selective binding and transcytosis of latex microspheres by rabbit intestinal M cells
M. Jepson (2008)
10.1016/S0264-410X(99)00025-0
Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein.
A. Coombes (1999)
10.1016/j.virol.2009.01.029
Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
Y. Yue (2009)
10.1016/S0927-7765(99)00157-5
The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.
Tobío (2000)
10.1016/S0168-3659(02)00140-2
Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles.
Ming-kung Yeh (2002)
10.1016/S0928-0987(97)10007-0
Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia.
S. McClean (1998)
10.1073/PNAS.0509541102
In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles.
Y. J. Kwon (2005)
10.1021/JS9801687
PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization.
S. Ando (1999)
10.1152/ajpgi.1998.275.1.G130
Kinetics of particle uptake in the domes of Peyer's patches.
R. Beier (1998)
10.1128/IAI.65.3.853-857.1997
Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.
K. Allaoui-Attarki (1997)
10.1016/S0264-410X(98)00382-X
Optimal induction of upper respiratory tract immunity to reovirus 1/L by combined upper and lower respiratory tract inoculation.
A. Thompson (1999)
10.1016/0169-409X(95)00131-P
The potential use of receptor-mediated endocytosis for oral drug delivery 1 PII of original article:
G. Russell-Jones (1996)
10.1016/j.vaccine.2009.05.091
Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.
Hesham H. Salman (2009)
10.4049/jimmunol.164.2.966
Lipopolysaccharide Activates Distinct Signaling Pathways in Intestinal Epithelial Cell Lines Expressing Toll-Like Receptors1
E. Cario (2000)
10.1002/PAT.280
PLA‐PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA
A. Vila (2002)
10.1007/978-1-4020-8412-6
Immunity against mucosal pathogens
M. Vajdy (2008)
10.1073/pnas.0703766104
Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination
T. Nochi (2007)
10.1016/S0264-410X(00)00215-2
CpG DNA is an effective oral adjuvant to protein antigens in mice.
M. McCluskie (2000)
10.1002/JMV.2144
Induction of mucosal IgA following intravaginal administration of inactivated HIV‐1‐capturing nanospheres in mice
M. Kawamura (2002)
10.1016/0264-410X(94)00008-B
Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.
E. Cahill (1995)
10.1136/mp.52.4.220
Cell adhesion molecules in the pathogenesis of and host defence against microbial infection.
J. Kerr (1999)
10.1016/j.vaccine.2009.02.071
Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
P. Minor (2009)
10.1016/J.VACCINE.2004.06.006
Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
G. Boland (2004)
10.1615/CRITREVTHERDRUGCARRIERSYST.V18.I4.10
Targeted delivery of drugs to the gastrointestinal tract.
E. Lavelle (2001)
10.4049/jimmunol.166.5.3451
Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract1
W. S. Gallichan (2001)
10.1007/978-1-4020-8412-6_3
The Mucosal B-Cell System
P. Brandtzaeg (2008)
10.1007/s00795-006-0335-6
Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue
Y. Fujimura (2006)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
10.1016/S0264-410X(02)00613-8
Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.
D. E. Katz (2003)
10.1016/j.vaccine.2008.12.004
New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model.
H. Florindo (2009)
10.1016/S0167-7799(98)01272-4
Single-administration vaccines: controlled-release technology to mimic repeated immunizations.
J. Cleland (1999)
Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells.
J. Pappo (1991)
10.1023/A:1025061317400
Toward Targeted Oral Vaccine Delivery Systems: Selection of Lectin Mimetics from Combinatorial Libraries
I. Lambkin (2004)
Intestinal absorption of PLAGA microspheres in the rat.
C. Damgé (1996)
10.1152/ajpcell.1998.275.1.C130
Regulation of ribosomal DNA transcription by insulin.
K. Hannan (1998)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1023/A:1011981610840
Utilizing Bacterial Mechanisms of Epithelial Cell Entry: Invasin-induced Oral Uptake of Latex Nanoparticles
N. Hussain (2004)
10.3109/10611869609015965
Nasal delivery of vaccines.
A. Almeida (1996)
10.1128/CDLI.7.6.899-903.2000
Calcium Phosphate Nanoparticle Adjuvant
Q. He (2000)
10.4049/jimmunol.181.1.17
Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31
H. Li (2008)
10.1007/82_2010_112
Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues.
C. Czerkinsky (2012)
10.4049/jimmunol.0802928
Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer1
S. Misumi (2009)
10.1021/mp8001254
Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus.
Yen Cu (2009)
10.1016/0378-5173(92)90162-U
Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat
P. U. Jani (1992)
10.1016/J.VACCINE.2003.10.020
Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.
A. M. Carcaboso (2004)
10.1165/RCMB.2003-0329OC
Toll-like receptors in normal and cystic fibrosis airway epithelial cells.
A. Muir (2004)
10.1016/S0264-410X(94)80038-2
Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres.
C. Tacket (1994)
10.1679/AOHC.63.81
The presence of specialized epithelial cells on the bronchus-associated lymphoid tissue (BALT) in the mouse.
M. Tango (2000)
10.1016/J.JCONREL.2004.04.026
Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.
A. Vila (2004)
10.1016/0304-4157(92)90038-C
Sterically stabilized liposomes.
M. Woodle (1992)
10.1023/A:1022271020390
Phagocytosis and Phagosomal Fate of Surface-Modified Microparticles in Dendritic Cells and Macrophages
L. Thiele (2004)
10.3109/10611860108997935
Transport of Nanoparticles Across the Rat Nasal Mucosa
J. Brooking (2001)
10.2147/NANO.2006.1.2.117
Chitosan nanoparticles for oral drug and gene delivery
Katherine Bowman (2006)
10.1016/J.IJPHARM.2007.07.035
In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
Fu Chen (2008)
10.1016/S0378-5173(02)00181-3
Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens.
E. Fattal (2002)
10.2147/BTT.S1877
Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
A. Monie (2008)
10.1023/A:1018901302450
Chitosan as a Novel Nasal Delivery System for Peptide Drugs
L. Illum (2004)
10.3109/10611869308996082
Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells.
M. Jepson (1993)
10.1111/j.1365-2567.2007.02641.x
The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response
Antoine Minne (2007)
10.1038/7385
Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
K. Roy (1999)
10.1007/978-1-4757-2046-4_18
Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response.
J. Eldridge (1989)
10.1016/S0168-3659(97)00145-4
The distribution of protein associated with poly(DL-lactide co-glycolide) microparticles and its degradation in simulated body fluids.
H. Takahata (1998)
10.1016/J.VACCINE.2003.12.032
Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Praveen Elamanchili (2004)
10.1211/0022357011776441
Chitosan: some pharmaceutical and biological aspects ‐ an update
A. K. Singla (2001)
Rapid insorption of small particles in the gut.
W. Sass (1990)
10.1016/J.JCONREL.2007.04.021
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination.
M. Garinot (2007)
10.1016/0264-410X(95)00184-3
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
A. Moore (1995)
10.1002/anie.200803526
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier.
Y. Wang (2008)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)
10.1016/J.IJPHARM.2005.03.035
Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.
C. Foged (2005)
10.1016/j.vaccine.2009.07.071
Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity.
Y. Yuki (2009)
10.3109/10611869509015936
Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence.
A. Florence (1995)
10.4049/jimmunol.169.4.2196
Characterization of CD8+ Effector T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain Ty21a Typhoid Vaccine1
R. Salerno-Gonçalves (2002)
10.1111/j.2042-7158.1990.tb07033.x
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
P. Jani (1990)
10.1016/j.biotechadv.2009.06.007
Application of chitosan microspheres for nasal delivery of vaccines.
M. L. Kang (2009)
10.1046/j.1365-2567.1998.00420.x
Intranasal immunization with polymer‐grafted microparticles activates the nasal‐associated lymphoid tissue and draining lymph nodes
Heritage (1998)
10.1016/j.imlet.2009.03.013
Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces
J. Mestecky (2009)
10.1016/S0378-5173(03)00266-7
Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66.
A. M. Carcaboso (2003)
10.1016/S0264-410X(01)00258-4
Targeting polymerised liposome vaccine carriers to intestinal M cells.
M. A. Clark (2001)
10.1016/S0169-409X(01)00167-3
Microparticles for intranasal immunization.
M. Vajdy (2001)



This paper is referenced by
10.1007/978-94-007-5869-8_37
Animal Vaccine Technology: An Overview
Li-Ting Cheng (2015)
10.1155/2013/835105
Novel Vaccine Adjuvants
A. Agrawal (2013)
10.4161/hv.20202
New vaccines needed for pathogens infecting animals and humans
Andres H. Gutiérrez (2012)
10.1155/2013/282913
Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research
E. Mata (2013)
10.1007/s11095-014-1540-y
Pulmonary Biodistribution and Cellular Uptake of Intranasally Administered Monodisperse Particles
Timothy M. Brenza (2014)
10.5772/INTECHOPEN.68235
Microparticle Vaccines Against Toxoplasma gondii
Chung‐Da Yang (2017)
10.1007/978-1-4614-9524-6_17
Vaccine Delivery Systems for Veterinary Immunization
J. M. Irache (2014)
10.1039/C5TB01623A
Peptide nanofiber-CaCO3 composite microparticles as adjuvant-free oral vaccine delivery vehicles.
Joshua D. Snook (2016)
Microparticle Vaccines Made from Biodegradable and Biocompatible Poly (Lactide-Co-Glycolide) Polymers
Chung-Da (2017)
10.1208/s12249-018-1254-2
Stability of Vaccines
N. Dumpa (2019)
10.1016/j.clim.2014.08.003
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.
N. Landry (2014)
10.1038/jid.2011.425
Applications of nanotechnology in dermatology.
L. DeLouise (2012)
10.2174/092986712803251548
Peptides as therapeutics with enhanced bioactivity.
D. Goodwin (2012)
10.1038/srep41886
Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus
L. Du (2017)
10.2147/IJN.S101881
Duality of β-glucan microparticles: antigen carrier and immunostimulants
K. Baert (2016)
APN-targeted β-glucan microparticles for oral immunisation
K. Baert (2015)
10.1081/e-ebpp-120050406
Microparticles: Biopolymer Microparticles for Medicine and Regenerative Medicine
K. Pal (2015)
10.1021/nn4006544
Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.
Dustin P Patterson (2013)
10.1002/cmdc.201200487
Modern Subunit Vaccines: Development, Components, and Research Opportunities
P. M. Moyle (2013)
10.4161/hv.28166
Recent advances in oral vaccine development
R. De Smet (2014)
10.1016/j.jconrel.2015.10.025
β-glucan microparticles targeted to epithelial APN as oral antigen delivery system.
K. Baert (2015)
10.1586/erv.12.135
Recent progress towards development of a Shigella vaccine
A. Camacho (2013)
10.1111/sji.12833
β‐glucan as a new tool in vaccine development
V. Vetvicka (2019)
10.2174/1566524011313040002
Single-Dose Microparticle Delivery of a Malaria Transmission-Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response
R. R. Dinglasan (2013)
10.1517/17425247.2014.924500
Orally active-targeted drug delivery systems for proteins and peptides
X. Li (2014)
10.2174/1573395514666180605092054
Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.
P. Kozlowski (2019)
10.1007/978-94-007-6645-7_37-1
Animal Vaccine Technology: A Review
L. Cheng (2014)
10.1016/B978-0-12-415847-4.00063-X
Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs)
Craig P McEntee (2015)
Semantic Scholar Logo Some data provided by SemanticScholar